



CIC invests in Inivata's £40 million series B funding round

Funds will accelerate commercialisation of InVisionFirst™-Lung Liquid Biopsy test and the development of the InVision® liquid biopsy platform into new indications

28 March 2019

Cambridge Innovation Capital plc (CIC), the venture capital investor focused on IP-rich technology and life science businesses in the Cambridge ecosystem, has participated in Inivata's Series B fundraising of £40 million (\$53 million). The first close of the financing occurred in August 2018, with the final tranche of the over-subscribed round being received in March 2019, based on strong delivery against corporate milestones.

The funds raised will be used to advance the US commercial roll-out of Inivata's InVisionFirst-Lung liquid biopsy test. Inivata recently received coverage determination for its InVisionFirst-Lung test for Medicare patients with advanced non-small cell lung cancer (NSCLC), paving the way for the test to be used in routine clinical care. This liquid biopsy test uses a simple blood draw to detect clinically relevant cancer mutations to provide molecular insights relevant to that patient. InVisionFirst-Lung is commercially available in the US.

The Series B financing will also enable the company to accelerate the development of the InVision® liquid biopsy platform into new indications to drive the future growth of the company.

Clive Morris, Chief Executive Officer at Inivata, said, *"This Series B financing allows us to commercialise our lead product in patients with advanced lung cancer following our positive reimbursement decision. We also have an exciting portfolio of future products that will be progressed in parallel to maximise the benefits of our industry-leading InVision Liquid Biopsy platform to patients. With these funds in place, we look forward to continuing our mission to transform the lives of cancer patients through the power of liquid biopsy."*

Michael Anstey, Investment Director at CIC added, *"Inivata has made great progress since our first investment when it was spun out of Cancer Research UK's laboratories in Cambridge. We are delighted to have helped Inivata develop from a start-up through to commercialising its products. InvisionFirst-Lung will improve the accuracy and the turnaround time of test results for patients with advanced non-small cell lung cancer. We look forward to continuing to support Inivata as it grows and develops its InVision platform further."*

ENDS

For more information, please contact:

Cambridge Innovation Capital

+44 (0)1223 764875

Michael Anstey, Investment Director

Louise Rich, Head of Investor Relations and Communications



Consilium Strategic Communications (City, financial PR)

Mary-Jane Elliott

Sukaina Virji

Lindsey Neville

+44 (0)20 3709 5700

CIC@consilium-comms.com

Holdsworth Associates (local and trade PR)

Rachel Holdsworth

+44 (0)1954 202789

Rachel@holdsworth-associates.co.uk

About Cambridge Innovation Capital plc

Cambridge Innovation Capital (CIC) is a venture capital investor focused on IP-rich technology and life science businesses in the Cambridge ecosystem. CIC is committed to building leading businesses from brilliant technologies. It combines a unique relationship with the University of Cambridge with deep financial and industry links to support these businesses as they seek to fulfil their potential to change the world of tomorrow.

For more information please visit www.cicplc.co.uk or follow us on Twitter at @CambsInnovation

About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The company's technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst™-Lung and its wider platform, which is applicable to a range of cancer types. The company has a CLIA laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.